Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar;65(3):386–393. doi: 10.2967/jnumed.123.266392

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

PMC Copyright notice

FIGURE 4. — 46-y-old woman with HER2-positive mBC and known osseous metastases. (A) ¹⁸F-FDG maximum-intensity projection PET image demonstrating numerous avid osseous metastases. (B and C) Maximum-intensity projection PET images of ⁸⁹Zr-ss-pertuzumab (B) and ⁸⁹Zr-DFO-pertuzumab (C) at 5 d after injection showing uptake within osseous metastases; however, ⁸⁹Zr-ss-pertuzumab detected more lesions and had higher lesion conspicuity and intensity of tracer uptake. The 3 hottest lesions with ⁸⁹Zr-ss-pertuzumab and ⁸⁹Zr-DFO-pertuzumab are denoted with arrows. ⁸⁹Zr-ss-pertuzumab PET/CT was performed 1 mo before ⁸⁹Zr-DFO-pertuzumab PET/CT.